Thanks for that in depth answer. I took some profits after Ridaforolimus got rejected by the FDA panel. I was shocked that Ariad went up after the rejection. It shows how hard it is to get anything through the FDA, and to conduct a valid, proper trial. There is so much potential for mistakes and errors along the way. Perhaps that is why even with so many promising drugs Cris is not higher.
I'm still holding about 2/3's of my Ariad, but may lighten up even more this week. I still feel like I should use mental stops on Ariad, but as some of the Ariad Hub writers always say, "know what you own," and it hasn't paid to use stops.
You have really toned down your criticism of Ariad, but I guess after the stock is up 5X this past year, there is not much to criticize.
Fortunately, my big winner this year has been Ariad and Apple. Apple has been amazing, as have been their products. To think that they will only sell 55 to 60 million I Pad 3's, as is forecast, is a joke. I think they could sell twice that worldwide. It is the most amazing thing I have ever held. They are going to earn over $50 per share in about a year. It is still cheap, although I am thinking about taking profits soon after a straight up run. Google is my next stock that I think will move quite a bit soon. I have had that one for several years. They will earn $45 per share next year. Intc is another one I like here. A correction is a possibility soon, though, and they all could take a hit.
To think that Ariad could really have two great cancer drugs that are properly tested and are effective, is quite an accomplishment. 113 could really be the key to their future and the stock price taking off, as well obviously as ponatinib. Rachel McMinn has been quite accurate in her assessment of Ariad. When she turns bullish that would be a great sign. It hasn't happened yet.
Cris is something that I will take seriously now, thanks to you. I'll start slowly, and get in soon. Thanks.
News 
Market Data 
Discover 
